Cilengitide hydrochloride | CAS# 188969-00-8 (HCl) | antineoplastic

MedKoo Cat#: 412898 | Name: Cilengitide hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cilengitide hydrochloride sis the salt form of Cilengitide, a cyclic Arg-Gly-Asp peptide with potential antineoplastic activity. Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis.

Chemical Structure

Cilengitide hydrochloride

CAS#188969-00-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 412898

Name: Cilengitide hydrochloride

CAS#: 188969-00-8 (HCl)

Chemical Formula: C27H41ClN8O7

Exact Mass:

Molecular Weight: 625.12

Elemental Analysis: C, 51.88; H, 6.61; Cl, 5.67; N, 17.93; O, 17.92

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

199807-35-7 (TFA) 188968-51-6 (free base) 188969-00-8 (HCl)

Synonym

Cilengitide hydrochloride; EMD85189; EMD 85189; EMD-85189

IUPAC/Chemical Name

2-((2S,5R,8S,11S)-5-benzyl-11-(3-guanidinopropyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid hydrochloride

InChi Key

JSBRBZVFFMRGCI-LOPTWHKWSA-N

InChi Code

InChI=1S/C27H40N8O7.ClH/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16;/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30);1H/t17-,18-,19+,22-;/m0./s1

SMILES Code

CC([C@@H]1N(C([C@H](NC([C@@H](NC(CNC([C@@H](NC1=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)Cc2ccccc2)=O)C)C.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 625.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: He F, Wang Y, Cai W, Li M, Dong L. Reversal of EGFR inhibitors' resistance by co-delivering EGFR and integrin αvβ3 inhibitors with nanoparticles in non-small cell lung cancer. Biosci Rep. 2019 Aug 28;39(8):BSR20181259. doi: 10.1042/BSR20181259. PMID: 31316001; PMCID: PMC6712436. 2: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jan-Feb;25(1):53-76. PMID: 12690708. 3: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jul-Aug;29(6):427-37. PMID: 17922073. 4: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 May;30(4):313-31. PMID: 18773127.

https://repositorio.uade.edu.ar/xmlui/handle/123456789/13471